Lundbeck Partners With AI Platform Cradle To Discover & Optimize Brain Disorder Treatments

H. Lundbeck A/S (Lundbeck), a biopharmaceutical company focused on brain health, and Cradle, an artificial intelligence (AI) platform for protein engineering, have announced a partnership to advance Lundbeck's biotherapeutics discovery and optimization efforts.

Brain disorders are estimated to affect more than half of the world's population. To help address this, Lundbeck is deploying Cradle's AI-powered protein design platform to develop candidates targeting neurological conditions.

The partnership establishes Lundbeck's first end-to-end AI-guided protein engineering workflow, in which experimental results are continuously fed back into the model to improve prediction accuracy and accelerate . . .